Business Wire

SHIPPEO

3.6.2024 10:01:28 CEST | Business Wire | Press release

Share
Unipart Logistics Selects Shippeo to Enhance Real-Time Visibility and Build Resilience and Sustainability for its Lead Logistics Partner Capability

Unipart, a supply chain solutions and performance improvement technologies business, has chosen Shippeo, a global leader in real-time multimodal transportation visibility as its supply chain visibility partner.

Leveraging Shippeo’s unparalleled real-time data and advanced transportation visibility technology, Unipart Logistics enhances its Lead Logistics Partner (LLP) capability to enable customers to better manage suppliers across road, sea, and air logistics, as well as warehousing and in-plant logistics. This empowers them to build resilience and reduce environmental impact across their global supply chain network.

Shippeo aggregates the industry’s largest global dataset, facilitating intelligent routing decisions across various modes of transportation worldwide. Through smarter carrier routing and management, ETA calculation, and in-transit management solutions, Shippeo will provide real-time insights, empowering users of the LLP to bolster supply chain resilience and sustainability, all while prioritising customer-centric operations. LLP users will also gain live insights into inventory, costs, OTIF, and scope 3 CO2 emissions throughout the supply chain, equipping logistics leaders with actionable data to drive informed business decisions. This continuous monitoring offers early alerts for supply chain issues and enables proactive mitigation or avoidance of disruptions.

Welcoming Unipart to Shippeo strengthens our UK presence and aligns with our shared vision for efficient, customer-centric, and sustainable supply chains. Their commitment to innovation and operational excellence perfectly complements Shippeo's real-time visibility platform. We're confident that our platform will empower Unipart to enhance their LLP platform, providing real-time visibility and control to manage their customer's supply chain, boost satisfaction, and achieve their sustainability goals. This partnership underscores our dedication to UK businesses and the increasing demand for real-time transportation visibility solutions," said Stuart Morrison, Shippeo Vice President, Northern Europe.

“Two trusted brands working in partnership delivering the complete end to end supply chain solution is critical to the success of any customer's supply chain. The need for real time visibility matched with the knowledge and expertise of Uniparts LLP offering deliver’s an efficient and sustainable solution. The data that the Shippeo system provides not only benefits the LLP and its customers for operational control, management and supply chain improvements but also supports and focuses all of our efforts on the need for a sustainable future,” said Lee Fox, Sector Strategy and Business Development Director for LLP at Unipart.

You can Shippeo and Unipart at Multimodal UK from June 11-13 in Birmingham. Don't miss the session with Shippeo’s Chief Product Officer, Anand Medepalli, and Unipart’s Director of Business Development and Sector Strategies, Adam Jones, at 10:30 AM GMT on June 11th. They will discuss "Shaping Logistics' Future: Shippeo & Unipart's Real-Time Visibility Story."

https://www.shippeo.com/press-releases/unipart-logistics-selects-shippeo-to-enhance-real-time-visibility-and-build-resilience-and-sustainability-for-its-lead-logistics-partner-capability

About Shippeo
Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more resilient, sustainable, and customer-centric supply chains. This is made possible with highly accurate real-time operational visibility and Transport Process Automation™ to streamline transportation processes, reduce latency and improve operational efficiency. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Ahold Delhaize, AkzoNobel, Amazon, Avery Dennison, Bosch Siemens Hausgeräte, Carrefour, Coca-Cola HBC, Jaguar Land Rover, Heineken, Kuehne+Nagel, L’Oréal, LVMH, Renault Group, Sabic, Saint-Gobain, Siemens Energy and XPO Logistics, trust Shippeo to track more than 32 million shipments per year across 110 countries. Learn more at www.shippeo.com, LinkedIn, Facebook, X (formerly Twitter)

About Unipart

Unipart Group is a leading provider of supply chain solutions and performance improvement technologies. It has deep expertise and breadth of capabilities in seven core sectors – automotive, rail and public transport, technology, healthcare, aerospace and defence, e-commerce, consumer and retail, and industrial sectors.

Unipart’s customer promise is: ‘To understand the real and perceived needs of our customers better than anyone else and to serve them better than anyone else.’ At the heart of delivering this is ‘The Unipart Way’, which is demonstrated in the way colleagues think, work and behave. The Unipart Way empowers more than 12,000 colleagues across operations in the UK and 20 international markets with a continuous improvement mindset, delivering operational excellence and added value for customers, everyday.

In 2023 Unipart delivered £1bn turnover. In 2024 it is celebrating the 50th Anniversary of the Unipart brand, having been a division within British Leyland in 1974 and becoming a private company through a management buyout in 1987.

Unipart is committed to setting the highest standards for colleague safety and wellbeing and sustainability. In 2023 it became the first organisation ever to be recognised with a world-class safety, wellbeing and sustainability ‘treble’ by the British Safety Council, and had its ambitious near-term and net-zero targets validated by the Science Based Targets initiative (SBTi).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240603664536/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release

Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w

Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release

Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –

The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release

New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &

Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release

Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste

The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release

Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye